Hints and tips:
...News round-up GAM board recommends £96mn takeover offer from Liontrust (FT) AstraZeneca chair says it is paying CEO enough to ward off US rivals (FT) Oaktree Capital’s Howard Marks to undergo cancer treatment...
...Deutsche Wohnen investor seeks injunction to block capital increase (FT) Veritas, Elliott consider $20bn-plus Athenahealth sale (Bloomberg) GE announces biggest acquisition under CEO Culp (Reuters) AstraZeneca...
...With the stock trading at more than 42 times forward earnings, a premium of nearly 70 per cent to global peers like AstraZeneca, further gains are likely to be limited....
...Its Crispr gene-editing technique has earned it an agreement with AstraZeneca and another unnamed “major” pharmaceutical company — and this is an end-market with a compound annual growth rate of 15-20 per...
...AstraZeneca fell 0.5 per cent. Photo: Bloomberg...
...Leading the losses are the dollar earning miners and pharmaceutical groups that have benefited so handsomely from the weakness of the pound, with Fresnillo down 2 per cent, Astrazeneca off 1.7 per cent and...
...AstraZeneca has set initial price guidance at 0.5 per cent to 0.55 per cent for its 5-year bond, while both AstraZeneca and Shell are both looking to pay about 1.5 per cent to borrow for 12 years....
...Other potential drugmakers who could be interested in acquiring Medivation include AstraZeneca and Roche....
...AstraZeneca has received Japanese marketing approval for the use of its Tagrisso drug for treating some forms of non-small cell lung cancer....
...named co-head of Emea healthcare at JPMorgan in early 2014 and has been involved in some of the largest healthcare transactions since then – including US drugmaker Pfizer’s attempted takeover of the UK’s AstraZeneca...
...Now that Abbvie’s £35bn bid for Shire has collapsed and the chances of Pfizer making a fresh £69bn bid for AstraZeneca have greatly diminished, it is also the sector’s biggest potential deal of the year....
...Pfizer is making the most of this aspect of its proposed takeover of AstraZeneca, in order to play down the reality that it would be a US takeover of a UK company....
...It accordingly takes regular pops at US bank bosses, such as Lloyd Blankfein of Goldman Sachs, and has sent the likes of AstraZeneca away with fleas in their ears on pay....
...There have also been leaks of talks – since abandoned – between Pfizer and AstraZeneca over a possible $100bn takeover....
...Pfizer raises bid for AstraZeneca to £50 per share. The move steps up pressure on the UK pharmaceuticals group to agree to a deal that would create the world’s biggest drugs company....
...NEWS AstraZeneca turns down “final” £69bn offer from Pfizer, shares drop 12 per cent....
...Shares of Alstom were suspended from trading in Paris today (Bloomberg) Shareholders at AstraZeneca have revolted against pay proposals for top executives....
...(Financial Times) Pfizer, the US pharmaceuticals group, has renewed its interest in a takeover of UK rival AstraZeneca, in what would be one of the global drugs industry’s largest ever deals....
...US political criticism of Pfizer’s bid for AstraZeneca ramped up late last week, partly as a result of concern in Maryland and Delaware – but also heightened attention from lawmakers worried about the tax...
...(Reuters) AstraZeneca urges David Cameron to be neutral over Pfizer’s £63bn takeover bid: Leif Johansson, AstraZeneca’s Swedish chairman, cautioned the UK prime minister that the government’s active engagement...
...(Financial Times) On the first of two days of parliamentary hearings, Pfizer acknowledged that its proposed £63bn takeover of AstraZeneca will lead to job cuts and a fall in research and development spending...
...The UK-listed drugmaker is the third FTSE 100 healthcare company to be targeted by a US rival so far this year after AstraZeneca fought off Pfizer and Smith & Nephew attracted tentative interest from Stryker...
...(Financial Times) Pfizer‘s chief executive flew into London on Tuesday to urge ministers to back its proposed £60bn takeover of AstraZeneca which he said would create a scientific powerhouse with a big...
...AstraZeneca is to buy out US partner Bristol-Myers Squibb from the pharmaceutical groups’ diabetes drug alliance in a deal worth up to $4.1bn....
...Lloyds, Shell, BAE Systems, AstraZeneca reporting....
International Edition